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AbSTRACT
background: The purpose of this study is to report the early 
experience with the use of the new CARDIA Ultrasept™ device 
for percutaneous occlusion of patent foramen ovale. Methods: 
Patients with patent foramen ovale with previous embolic 
events, of any age or weight, or migraine with poor clinical 
control, were selected by transesophageal echocardiography. 
Efficacy criteria included lack of residual shunt at the trans-
esophageal echocardiogram with microbubble testing after 6 
months and no recurrence of neurologic events. No patients 
were excluded based on morphological patent foramen ovale 
criteria. Results: From April 2011 to May 2012, 22 patients 
(6 males and 16 females) with ages ranging from 16 to 68 
years were submitted to the occlusion procedure. Only one 
patient had no history of stroke or transient ischemic attack, 
but migraine with poor clinical response. None of the patients 
had atrial septal aneurysms. The device was implanted in 
all cases, 23 devices were used and the 25 mm device was 
used most often. Only one patient presented residual shunt 
at the 1-month follow-up echocardiogram and remains under 
observation. There have been no recurrences to date. There 
were two minor complications and no deaths. Conclusions: The 
CARDIA Ultrasept™ device is safe, effective and easy to use. 
It must be further evaluated in more complex cases, such as 
larger patent foramen ovales and with atrial septal aneurysms.
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RESUMO
Experiência Inicial com a Nova Prótese CARDIA 
UltraseptTM para Fechamento do Forame Oval 
Patente: Ainda uma boa Opção
Introdução: Neste trabalho os autores visam a apresentar sua 
experiência inicial com o uso da nova prótese CARDIA Ultra-
septTM para fechamento percutâneo do forame oval. Métodos: 
Foram selecionados por ecocardiograma transesofágico pacientes 
portadores de forame oval com eventos embólicos prévios, de 
qualquer idade e peso, ou enxaqueca de difícil controle clínico. 
Os critérios de eficácia incluíram ausência de shunt residual 
pelo ecocardiograma transesofágico com teste de microbolhas 
após seis meses e ausência de recidiva de eventos neurológicos. 
Não foram excluídos pacientes com base em dados morfológicos 
do forame oval. Resultados: De abril de 2011 a maio de 2012 
foram submetidos ao procedimento de oclusão 22 pacientes (6 
do sexo masculino e 16 do sexo feminino) com idades entre 
16 e 68 anos. Apenas uma paciente não tinha antecedente 
de acidente vascular cerebral ou ataque isquêmico transitório 
e sim enxaqueca de difícil controle clínico. Nenhum paciente 
apresentou aneurisma de septo atrial. Foi possível o implante em 
todos os casos, sendo utilizados 23 dispositivos. O dispositivo 
mais utilizado foi o de 25 mm. Apenas um paciente ficou com 
shunt residual ao ecocardiograma de um mês e continua em 
seguimento. Não houve recidivas de eventos até o momento. 
Houve duas complicações menores e não houve óbitos. Con-
clusões: O dispositivo CARDIA UltraseptTM é seguro, de fácil 
manuseio e eficaz. Ainda necessita ser mais bem avaliado em 
casos mais complexos, como os forames ovais maiores e com 
aneurisma do septo atrial.
DESCRITORES: Forame oval patente. Cateterismo cardíaco. 
Próteses e implantes.
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T he foramen ovale, which is a crucial structure for foetal circulation, remains patent in 25% to 30% of the adult population.1,2 By allowing the passage 
of the interatrial flow from right to left, the patent fo-
ramen ovale is now recognized to be associated with 
cerebral thromboembolic events3–9 and migraines with 
aura.10–12 Several case series studies suggest that occlu-
sion by the percutaneous technique may be indicated 
in these situations,13–17 and may even be more effective 
than medical therapy in the secondary prevention of 
cerebrovascular event recurrence in patients with a pa-
tent foramen ovale-related ischemic stroke or transient 
ischemic attack (TIA).16
Several devices have been developed for patent 
foramen ovale (PFO) occlusion. The CARDIA prostheses 
(Cardia Inc. – Eagan, MN, USA) have been available 
since 1998 and have been redesigned several times,18–20 
although the redesigned prostheses preserve the same 
basic structural concept of two IvalonTM (polyvinyl 
alcohol) discs supported by nitinol struts.
The seventh-generation CARDIA prostheses, termed 
Ultrasept™, maintains the basic concepts described 
above, but now both discs have rounded edges to 
minimize the risk of erosion and/or perforations.
The objective of this study was to report an initial 
experience using this prosthetic device for PFO occlusion.
Methods
study Project
This prospective, single-center single-arm study 
included all patients who underwent foramen ovale 
occlusion with the CARDIA UltraseptTM prosthesis.
Patients of any age and weight who had the follo wing 
symptoms were selected: one or more neurological events 
with no definite causes (cryptogenic) and a diagnosis based 
on clinical and/or neurological imaging; and migraine 
with aura, with an unsatisfactory response to traditional 
medication or prophylactic clinical indication, as formalized 
by the attending physician in risk PFO with the passage 
of large bubbles during normal breathing.
The cases were selected by a transesophageal 
echocardiogram with a positive bubble test, with 
an agitated saline solution while breathing sponta-
neously or after the Valsalva manoeuver. No type of 
foramen was eliminated based on its morphological 
characteristics.
All procedures were performed with the prior ad-
ministration of 200 mg of acetylsalicylic acid.
device description
The new version, as did the previous versions, 
consists of two round discs of Ivalon™ but is supported 
by six rounded nitinol loops instead of struts (Figure 1).
The prostheses are available in Brazil in sizes of 20 
mm, 25 mm and 30 mm, which correspond to the length 
of the nitinol loops. The device size was selected on a 
case-by-case basis, according to the length and opening 
of the produced tunnel, the stability and consistency 
of the septum primum, and the presence or absence 
of lipomatous degeneration of the septum secundum.
Along with the device, a flexible bioptome was 
offered, with a safety lock, to capture the contact pin 
in the center of the right disc. This bioptome allows 
for the introduction of the prosthesis into a transparent 
cylinder carrier, which has a distal end that can be 
dilated to enable better adaptation to the flexed disc 
carrier. The other end of the cylinder fits into a short 
sheath and is transparent, single-sized, and features a 
hemostatic valve (Figure 2). The prosthesis slides easily 
from the carrier to the short sheath and thus can be 
transferred to the long sheath (Mullins), which will lead 
it to the heart, pushed by the long bioptome cable. For 
the aforementioned prosthesis sizes, Mullins sheaths of 
10-F to 11-F are required.
The CARDIA UltraseptTM prosthesis can be easily 
recaptured and repositioned while attached to the 
delivery system.
Figure 1 – Details of the new version of the CARDIA prosthesis. A, 
Left surface of the disc. Note the metal completely covered by the 
Ivalon™ sponges. B, Surface of the right disc, which is smaller than 
the left one, with the nitinol loops and the central capture pin clearly 
visible. C, Prosthesis profile view, held by the bioptome.
Figure 2 – Details of the carrier system. A, Carrier with a dilated 
distal extremity to better guide the device disks, thereby minimizing 
the trauma to the Ivalon™ sponges. The short sheath, also trans-
parent, fits perfectly into the carrier, facilitating the prosthesis 
delivery. B, Detail of the steps of prosthesis delivery, from left to 
right: observe the prosthesis attached to the bioptome, the carrier 
and the short sheath.
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Implantation technique
The technique employed in all cases was the 
same used in previous versions and has already been 
described.20
Follow-up
All patients were maintained on dual antiplatelet 
therapy with 200 mg/day of acetylsalicylic acid and 75 
mg/day of clopidogrel for three months, followed by 
the isolated use of acetylsalicylic acid at the same dose 
between the third and sixth months after the procedure. 
The follow-up was conducted by clinical evaluations and 
transthoracic echocardiograms immediately after the pro-
cedure and after one and three months. A transesophageal 
echocardiography with the bubble test using an agitated 
saline solution was performed after six months.
statistical Analysis
Continuous variables were expressed as means 
± standard deviations, and categorical variables were 
expressed as numbers and percentages.
Results
From April of 2011 to May of 2012, 22 patients 
underwent the percutaneous occlusion of a patent fo-
ramen ovale with the CARDIA UltraseptTM prosthesis. 
Only six patients were males. Their ages ranged from 
16 to 68 years (45.7 ± 13.1 years). All patients had 
a prior clinical picture of ischemic cerebral episodes 
(CVA/TIA), except one, in whom the indication was 
the difficult clinical management of migraines (Table).
TAbLE 
Patient characteristics
Identification
Age
(years) Gender
Stroke/
TIA
Tunnel
(mm)
Opening
(mm)
Produced
opening
(mm)
Prosthesis
(mm)
Immediate 
occlusion 
(mm)
MSO 32 M Yes 8 3 7 25 Yes 
MFDS 42 F Yes 10 4 9.5 30 Yes 
MAS 34 F Yes 4 3 5 20 Yes 
ESF 42 F Yes 6 1 2.5 20 Yes 
JBS 46 F Yes 10 3 4 25 Yes 
SK 68 F Yes 9 3 9 30 Yes 
ACA 51 F Yes 10 4.5 6.5 25 Yes 
CCC 37 F Yes 8 2.5 4.4 20 Yes 
WAS 64 M Yes 7 5 9 25 Yes 
EPI 57 M Yes 10 5 9.6 25 Yes 
LJSS 60 M Yes 6 2 5.4 20 Yes 
AFN 63 F Yes 9 2 9 25 ± 30 Yes 
LPC 55 F Yes 6 2.5 5.6 20 Yes 
RMB 16 F Yes 8 3 7 20 Yes 
ICSB 46 F Yes 8 6 8 25 Yes 
BCP 29 F Yes 7 2 5 25 Yes 
SAML 44 F Yes 10 2 5 25 No 
CAVZ 48 M Yes 12 2 4.5 20 Yes 
MGOA 57 F Yes 10 4 5 25 Yes 
MMZ 35 F No* 4 1.3 5 25 Yes 
BCC 28 F Yes 9 1 4 20 Yes 
WLSS 52 M Yes 8 3 5 20 Yes 
* Migraine with poor clinical control
TIA = transient ischemic attack; F = female; M = male.
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The lengths of the tunnels ranged from 4–12 mm 
(8.13 ± 2 mm) with non-induced openings of 1–6 
mm (2.94 ± 1.30 mm). The variation of the produced 
opening obtained with the rigid guidewire positioned 
behind the foramen was 4–9.5 mm (6.13 ± 2.01 mm).
The implant was feasible in all cases. A total of 23 
devices were used in 22 patients. The size used most 
often was 25 mm (47.8% of patients), followed by the 
20-mm size (39.1%) and the 30-mm size (Figure 3).
The patient who required two prostheses (AFN) 
had a thickened septum secundum due to lipomatous 
degeneration and a hypermobile septum primum. A 
25-mm device was implanted, which was fixed only 
in the septum primum, keeping the foramen open 
with the passage of large bubbles from right to left. 
In the same procedure, a second 30-mm device was 
implanted without difficulties; this device was able to 
capture both the lipomatous septum and the first device, 
completely occluding the residual defect. The bubble 
test conducted after implantation showed no passage 
of bubbles into the left atrium.
In one patient (JBS), the prosthesis right disk was 
trapped in the Eustachian valve, which was quite 
large, and could not be configured properly, keeping 
the prosthesis open with a large shunt inside it. After 
several unsuccessful attempts to loosen the right disc, 
the device was released from the delivery cable on the 
assumption that it would become free and then achieve 
the desired configuration, thus reducing the prosthesis 
profile. As that outcome did not occur, the right disc 
was recaptured with a 15-mm snare catheter and re-
introduced into the long sheath. The set was advanced 
through the septum into the left atrium roof, and the 
prosthesis was repositioned with the right disk always 
configured near the extremity of the long sheath to 
prevent it from being arrested again in the large valve. 
The prosthesis was released, and the bubble test con-
ducted after the release showed no passage of bubbles 
through the interatrial septum (Figure 4).
One patient (SAML) presented a minimal additional 
orifice near the inferior vena cava. The foramen was closed 
with a 25-mm prosthesis. The bubble test showed no 
subsequent passage of bubbles from right to left through 
the second orifice, which was allowed to remain open. 
There were two minor immediate complications. One 
patient (AFN) had bleeding in the endotracheal tube after 
implantation, presumably due to an entrance laceration 
Figure 4 – Details of the implant in the patient JBS. A, Prosthesis released after the first implant, with the right disk fixed in the Eustachian valve, 
holding it open with a large residual shunt. B, Right disk captured by the loop catheter (Amplatz Goose Neck snare, 15 mm) and retracted to be 
pulled again into the long sheath for a second implant. C, Repositioned prosthesis. After being released from the snare, it reached the correct posi-
tion. In this profile, the residual shunt is no longer observed. The control bubble test was negative.
Figure 3 – Details of the implant. A, Prosthesis positioned in the atrial septum, completely configured but still attached to the delivery system. 
B, Prosthesis after release. Note that the prosthesis changes its spatial position and adapts perfectly to the plane of the septum, free of the weight 
of the delivery system. C, Released prosthesis, observed through the left atrium, on three-dimensional echocardiography.
A B C
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of the left superior pulmonary vein caused by the long 
sheath. She was under observation in the Intensive Care 
Unit, but transfusion or any other surgical measure was 
not required. The patient was discharged the next day 
in good status. The second patient (BCP) had a fresh 
thrombus that was unorganized, adhered to the left 
prosthesis disc, and was visualized by transesophageal 
echocardiography during the procedure. The heparin dose 
was increased to 10,000 U. The prosthesis and the long 
sheath were withdrawn slowly and thoroughly washed 
with heparinized saline solution. Then, after careful 
ins pection, the sheath and prosthesis were reintroduced, 
and the new implant procedure was uneventful. The 
patient showed no signs of neurological involvement 
and was discharged in good status.
Over half of the patients (57.1%) reached the 
six-month follow-up. There has been no recurrence of 
neurological events in any of the cases to date. The 
patient with prior migraine (MMZ) had headache with 
aura in the first month after implantation, although 
less severe than the previous episodes. Another pa-
tient (CCC) showed an allergy to clopidogrel and was 
treated with aspirin only. One patient (SAML) showed 
a residual shunt through the interior of the prosthesis 
on the control transthoracic echocardiogram after one 
month. This patient is being monitored and has had no 
complications. The others were adequately occluded 
(Figure 5). There were no deaths in the present series.
dIscussIon
The percutaneous occlusion of patent foramen 
ovales is currently performed in most hemodynamics 
services worldwide. It has proved to be a safe, effec-
tive, and easily reproducible procedure with excellent 
results, especially with the new generations of prostheses 
developed specifically for this purpose.1,12,16,21–28
There are few studies in the literature using the 
CARDIA prosthesis. In this new version, the round shape 
of the two discs has less risk of erosion or perforation. 
Notably, the left disc nitinol loops are located underneath 
the Ivalon™ sponge, reducing the risk of thrombosis 
and promoting more homogeneous endothelialisation.
The configuration of the prosthesis is facilitated by 
the use of the carrier and the short transparent sheath, 
which enables the easy detection of the presence of 
air within the system.
Despite the introduced changes, high-profile sheaths 
remain more necessary than desired. However, as they are 
introduced by venous access, the risk of complications is 
low, even in children. By always using the sheaths with 
the adequate gauge recommended by the manufacturer, 
there was no difficulty in loading the prosthesis, which 
slid easily through the interior of the sheath in all cases.
The implantation was performed without difficulty, 
and the technique does not differ from those described 
for other prostheses with the same purpose. Compared 
with previous models of the device, slightly more space 
might be needed for the right disk configuration, which 
could explain the case (JBS) in which it was trapped 
by the large Eustachian valve.
A point to be considered is the possibility of the 
bioptome becoming entrapped in the disk loops im-
mediately after prosthesis release from the delivery 
system, as previously observed. It is important to always 
keep the bioptome open during withdrawal until its 
introduction into the long sheath. If any resistance or the 
movement of the prosthesis along with it is noticed, the 
right disc should not be pulled, which would increase the 
risk of prosthesis dislocation; instead, the open bioptome 
should be carefully rotated until it is released from the 
captured snare. Another suggestion is to keep the long 
sheath near the bioptome at the time of the opening, 
in order to prevent an excessive lateral displacement of 
the cable, which could increase the risk of the bioptome 
jaws becoming trapped in the right disc loops.
The visibility on the transesophageal echocardio-
graphy is quite satisfactory, although a less experienced 
echocardiographist might occasionally be confused re-
garding the contour of the left disc, which may appear 
to be maladapted to the septum, especially while the 
prosthesis is attached to the delivery system. Normally, 
after release, it adapts best to the plane of the septum 
and its correct positioning then becomes clear. A low 
device profile was observed in all cases and good 
adaptability to the defect, with good rates of immediate 
closure, either by color Doppler echocardiogram or 
through the bubble test performed after implantation.
conclusIons
The CARDIA UltraseptTM device is durable, easy to 
use, fully repositionable and reimplantable, has a low 
profile and has good occlusion rates compared with 
similar prostheses.
The short time of the follow-up did not allow for 
drawing conclusions regarding the effectiveness of the 
endothe lialisation on the rates of event recurrence or 
long-term complications.
Figure 5 – Details of the control transesophageal echocardiography, 
six months after implantation. A, The prosthesis is well-positioned in 
the atrial septum. B, Bubble test, showing no bubbles passing into the 
left atrium, confirming the effectiveness of the device.
A B
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The initial results are encouraging in all cases. 
Although this new device was used in septa with great 
mobility, its use in more complex scenarios (e.g., cases 
with large septal aneurysms) has yet to be tested.
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